keyword
https://read.qxmd.com/read/38599194/considering-the-cellular-landscape-in-marrow-stimulation-techniques-for-cartilage-repair
#21
REVIEW
Maddie Hasson, Lorenzo M Fernandes, Hanna Solomon, Tristan Pepper, Nicholas L Huffman, Saitheja A Pucha, Jason T Bariteau, Jarred M Kaiser, Jay M Patel
BACKGROUND: Marrow stimulation is a common reparative approach to treat injuries to cartilage and other soft tissues (e.g., rotator cuff). It involves the recruitment of bone marrow elements and mesenchymal stem cells (MSCs) into the defect, theoretically initiating a regenerative process. However, the resulting repair tissue is often weak and susceptible to deterioration with time. The populations of cells at the marrow stimulation site (beyond MSCs), and their contribution to inflammation, vascularity, and fibrosis, may play a role in quality of the repair tissue...
April 10, 2024: Cells, Tissues, Organs
https://read.qxmd.com/read/38594416/comparable-outcomes-of-allogeneic-peripheral-blood-versus-bone-marrow-hematopoietic-stem-cell-transplantation-from-a-sibling-donor-for-pediatric-patients
#22
JOURNAL ARTICLE
Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyery Kim, Hyun Jin Park, Hyoung Jin Kang
Traditionally, bone marrow (BM) has been preferred as a source of stem cells (SCs) in pediatric hematopoietic SC transplantation (HSCT); however, the use of peripheral blood SCs (PBSC) has recently increased. With advancing graft-versus-host disease (GVHD) prophylaxis, whether the BM is still a better SC source than PB in sibling donor HSCT remains controversial. Here, we compared the results of BM transplantation (BMT) and PBSC transplantation (PBSCT) in pediatric patients with malignant or non-malignant diseases receiving sibling HSCT using a total of 7...
April 10, 2024: Annals of Hematology
https://read.qxmd.com/read/38594285/comparison-of-the-2022-world-health-organization-classification-and-international-consensus-classification-in-myelodysplastic-syndromes-neoplasms
#23
JOURNAL ARTICLE
Wan-Hsuan Lee, Chien-Chin Lin, Cheng-Hong Tsai, Feng-Ming Tien, Min-Yen Lo, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Shan-Chi Yu, Ming-Chih Liu, Chang-Tsu Yuan, Yi-Tsung Yang, Ming-Kai Chuang, Bor-Sheng Ko, Jih-Luh Tang, Hsun-I Sun, Yi-Kuang Chuang, Hwei-Fang Tien, Hsin-An Hou, Wen-Chien Chou
In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS) have been proposed: the International Consensus Classification (ICC) and the 2022 World Health Organization (WHO-2022) classification. These two contemporary systems exhibit numerous shared features but also diverge significantly in terminology and the definition of new entities. Thus, we retrospectively validated the ICC and WHO-2022 classification and found that both systems promoted efficient segregation of this heterogeneous disease...
April 9, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38594129/soho-state-of-the-art-updates-and-next-questions-an-update-on-higher-risk-myelodysplastic-syndromes
#24
REVIEW
Michael J Hochman, Amy E DeZern
Higher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-MDS) are a heterogenous group of clonal myeloid-lineage malignancies often characterized by high-risk genetic lesions, increased blood transfusion needs, constitutional symptoms, elevated risk of progression to acute myeloid leukemia (AML), and therapeutic need for allogeneic bone marrow transplantation...
March 18, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38589766/nephronophthisis-13-caused-by-wdr19-variants-with-pancytopenia-case-report
#25
JOURNAL ARTICLE
Yu Tanaka, Tomoko Horinouchi, Yuta Inoki, Yuta Ichikawa, Chika Ueda, Hideaki Kitakado, Atsushi Kondo, Nana Sakakibara, China Nagano, Yoshihiko Yano, Norishige Yoshikawa, Naoya Morisada, Kandai Nozu
We present a case of nephronophthisis 13 that resulted from WDR19 variants. The patient, a nine-year-old Japanese boy, had detection of mild proteinuria during a school urine screening. Urinalysis revealed mild proteinuria without hematuria. Blood tests indicated pancytopenia, mild elevation of liver enzymes, and kidney dysfunction. Ultrasound examination disclosed hepatosplenomegaly. Abdominal computed tomography and bone marrow assessments ruled out malignant tumors. Subsequent kidney and liver biopsies suggested nephronophthisis and congenital hepatic fibrosis...
April 8, 2024: CEN Case Reports
https://read.qxmd.com/read/38584071/exploring-novel-protein-biomarkers-for-early-stage-diagnosis-and-prognosis-of-t-acute-lymphoblastic-leukemia-t-all
#26
JOURNAL ARTICLE
Vivek Singh, Ranjana Singh, Rashmi Kushwaha
Efficient classification of T-acute lymphoblastic leukemia (T-ALL) involves considering various factors, such as age, white blood cell count, and chromosomal alterations. However, studying protein markers are crucial to improving T-ALL patients' diagnosis and treatment. A study analyzing the expression of proteomes was conducted to identify promising early-stage biomarkers for T-ALL patients METHODS: Label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to analyze the blood proteins of both patients and healthy individuals to identify new biomarkers for T-ALL...
March 28, 2024: Hematology, Transfusion and Cell Therapy
https://read.qxmd.com/read/38582746/consensus-of-the-brazilian-association-of-hematology-hemotherapy-and-cellular-therapy-on-patient-blood-management-intraoperative-hemostasis-and-volume-replacement
#27
JOURNAL ARTICLE
Juan Carlos Montano-Pedroso, Roseny Dos Reis Rodrigues, Fernanda Vieira Perini, Luciana Correa Oliveira, Enis Donizetti, Silvia Renata Cornélio Parolin Rizzo, Guilherme Rabello, Dante Mario Langhi Junior
Hemostasis plays a critical role in surgical procedures and is essential for a successful outcome. Advances in hemostatic agents offer new approaches to controlling bleeding thereby making surgeries safer. The appropriate choice of these agents is crucial. Volume replacement, another integral part of Patient Blood Management (PBM), maintains adequate tissue perfusion, preventing cellular damage. Individualization in fluid administration is vital with the choice between crystalloids and colloids depending on each case...
March 21, 2024: Hematology, Transfusion and Cell Therapy
https://read.qxmd.com/read/38582745/causes-and-risk-factors-for-early-death-in-adult-patients-with-acute-promyelocytic-leukemia-a-real-life-experience
#28
JOURNAL ARTICLE
Heloísa Maria Farias Fontes, Júlia Peres de Freitas, José Henrique Vanderlei Oliveira, Édyla Almeida de Sousa Moraes, Eduardo Magalhães Rego, Raul Antônio Morais Melo
INTRODUCTION: Early Death (ED) remains challenging in newly diagnosed acute promyelocytic leukemia (APL), especially in developing countries. The clinical and laboratory profile at diagnosis were evaluated and causes and risk factors were investigated in adult APL patients. METHOD: A retrospective real-life analysis of 141 medical records was performed of patients diagnosed with APL between 2007 and 2018, whether they were treated with the IC-APL 2006 protocol or not...
March 21, 2024: Hematology, Transfusion and Cell Therapy
https://read.qxmd.com/read/38582286/evaluation-of-circulating-endothelial-cells-cecs-as-direct-marker-of-endothelial-damage-in-allo-transplanted-patients-at-high-risk-of-hepatic-veno-occlusive-disease-sinusoidal-obstruction-syndrome-vod-sos
#29
JOURNAL ARTICLE
M Farina, M C Scaini, A Facchinetti, A Leoni, S Bernardi, C Catoni, E Morello, V Radici, Filippo Frioni, E Campodonico, G Traverso, G Cavallaro, A Olivieri, P Galieni, N Di Renzo, F Patriarca, P Carluccio, C Skert, E Maffini, S Pellizzeri, G Campisi, F Re, E Benedetti, A Rosato, C Almici, P Chiusolo, J Peccatori, M Malagola, C Poggiana, D Russo
Sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD), is a rare but potentially fatal complication following allogenic hematopoietic cell transplantation (allo-HCT). Timely identification of SOS/VOD for prompt treatment is critical, but identifying a VOD predictive biomarker is still challenging. Given the pivotal role of endothelial dysfunction in SOS/VOD pathophysiology, the CECinVOD study prospectively evaluated Circulating Endothelial Cells (CEC) levels in patients undergoing allo-HCT with myeloablative conditioning regimens (MAC) to investigate their potential in predicting and diagnosing SOS/VOD...
April 4, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38581695/prognostic-impact-of-number-of-induction-courses-to-attain-complete-remission-in-patients-with-acute-myeloid-leukemia-transplanted-with-either-a-matched-sibling-or-human-leucocyte-antigen-10-10-or-9-10-unrelated-donor-an-acute-leukemia-working-party-european
#30
JOURNAL ARTICLE
Justin Loke, Myriam Labopin, Charles Craddock, Gérard Socié, Tobias Gedde-Dahl, Didier Blaise, Edouard Forcade, Urpu Salmenniemi, Anne Huynh, Jurjen Versluis, Ibrahim Yakoub-Agha, Hélène Labussière-Wallet, Johan Maertens, Jakob Passweg, Claude Eric Bulabois, Ludovic Gabellier, Stephan Mielke, Cristina Castilla-Llorente, Eric Deconinck, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
INTRODUCTION: For the majority of patients with acute myeloid leukemia (AML) an allogeneic stem cell transplant (SCT) in first complete remission (CR) is preferred. However, whether the number of courses required to achieve CR has a prognostic impact is unclear. It is unknown which factors remain important in patients requiring more than one course of induction to attain remission. METHODS: This Acute Leukaemia Working Party study from the European Society for Blood and Marrow Transplantation identified adults who received an allograft in first CR from either a fully matched sibling or 10/10 or 9/10 human leucocyte antigen (HLA)-matched unrelated donor (HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ)...
April 6, 2024: Cancer
https://read.qxmd.com/read/38581299/effects-of-cd34-cell-dose-on-engraftment-and-long-term-outcomes-after-allogeneic-bone-marrow-transplantation
#31
JOURNAL ARTICLE
Takashi Oyama, Shin-Ichiro Fujiwara, Ryutaro Tominaga, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Takashi Ikeda, Shin-Ichiro Kawaguchi, Yumiko Toda, Takashi Nagayama, Kento Umino, Daisuke Minakata, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ikuko Otsuki, Ken Ohmine, Yoshinobu Kanda
BACKGROUND: The number of CD34+ cells in the graft is generally associated with time to engraftment and survival in transplantation using cord blood or allogeneic peripheral blood stem cells. However, the significance of abundant CD34+ in bone marrow transplantation (BMT) remained unclear. METHODS: We retrospectively reviewed 207 consecutive adult patients who underwent their first BMT at Jichi Medical University between January 2009 and June 2021. RESULTS: The median nucleated cell count (NCC) and CD34+ cell dose were 2...
April 2024: Clinical Transplantation
https://read.qxmd.com/read/38580835/pre-frailty-after-blood-or-marrow-transplantation-and-the-risk-of-subsequent-mortality
#32
JOURNAL ARTICLE
Nora Balas, Joshua S Richman, Wendy Landier, Sadeep Shrestha, Katia J Bruxvoort, Lindsey Hageman, Qingrui Meng, Elizabeth Ross, Alysia Bosworth, F Lennie Wong, Ravi Bhatia, Stephen J Forman, Saro H Armenian, Daniel J Weisdorf, Smita Bhatia
We examined the prevalence, risk factors, and association between pre-frailty and subsequent mortality after blood or marrow transplantation (BMT). Study participants were drawn from the BMT Survivor Study (BMTSS) and included 3346 individuals who underwent BMT between 1974 and 2014 at one of three transplant centers and survived ≥2 years post-BMT. Participants completed the BMTSS survey at a median of 9 years from BMT and were followed for subsequent mortality for a median of 5 years after survey completion...
April 5, 2024: Leukemia
https://read.qxmd.com/read/38580496/consensus-of-the-brazilian-association-of-hematology-hemotherapy-and-cellular-therapy-on-patient-blood-management-inadvertent-intraoperative-hypothermia
#33
JOURNAL ARTICLE
Enis Donizetti, Fernanda Vieira Perini, Roseny Dos Reis Rodrigues, Juan Carlos Montano-Pedroso, Luciana Correa Oliveira, Silvia Renata Cornélio Parolin Rizzo, Guilherme Rabello, Dante Mario Langhi
Hemostasis plays a critical role in surgical procedures and is essential for a successful outcome. Advances in hemostatic agents offer new approaches to controlling bleeding thereby making surgeries safer. The appropriate choice of these agents is crucial. Volume replacement, another integral part of Patient Blood Management (PBM), maintains adequate tissue perfusion, preventing cellular damage. Individualization in fluid administration is vital with the choice between crystalloids and colloids depending on each case...
March 23, 2024: Hematology, Transfusion and Cell Therapy
https://read.qxmd.com/read/38580495/consensus-of-the-brazilian-association-of-hematology-hemotherapy-and-cellular-therapy-on-patient-blood-management-acute-normovolemic-hemodilution-and-intraoperative-autotransfusion
#34
JOURNAL ARTICLE
Fernanda Vieira Perini, Juan Carlos Montano-Pedroso, Luciana Correa Oliveira, Enis Donizetti, Roseny Dos Reis Rodrigues, Silvia Renata Cornélio Parolin Rizzo, Guilherme Rabello, Dante Mario Langhi Junior
Autologous blood transfusion can be achieved through different techniques, including by the patient donating blood before surgery (pre-deposit), collecting blood from the patient immediately before the operation and replacing the volume with colloids or plasma expanders (acute normovolemic hemodilution) or through the salvage of lost blood, during or immediately after surgery, and its retransfusion after washing (intraoperative or postoperative recovery). We will focus on the two methods used intraoperatively that are of fundamental importance in the management and conservation of the patient's own blood...
March 27, 2024: Hematology, Transfusion and Cell Therapy
https://read.qxmd.com/read/38580494/consensus-of-the-brazilian-association-of-hematology-hemotherapy-and-cellular-therapy-on-patient-blood-management-assessment-and-management-of-postoperative-anemia
#35
JOURNAL ARTICLE
Bruno Deltreggia Benites, Mariana Munari Magnus, Lorena Costa, Denise Menezes Brunetta, Roseny Dos Reis Rodriges, Susankerle de Oliveira Costa Alves, Gil Cunha De Santis, Silvia Renata Cornélio Parolin Rizzo, Guilherme Rabello, Dante Mario Langhi Junior
Postoperative anemia is a complex clinical issue that requires attention due to its ramifications on the patient's recovery and prognosis. Originating from multiple determinants, such as intraoperative blood loss, hemolysis, nutritional deficiencies, systemic inflammation and impact on the bone marrow, postoperative anemia has varied and often challenging presentations. Patients undergoing major surgical procedures, in particular, are susceptible to developing anemia due to the considerable associated blood loss...
March 19, 2024: Hematology, Transfusion and Cell Therapy
https://read.qxmd.com/read/38579107/body-composition-and-late-occurring-chronic-health-conditions-after-autologous-stem-cell-transplantation-for-lymphoma
#36
JOURNAL ARTICLE
Smith Giri, Christian Harmon, Wendy Landier, Yanjun Chen, Jessica Wu, Lindsey Hageman, Nora Balas, Liton Francisco, Alysia Bosworth, Daniel J Weisdorf, Stephen J Forman, Saro H Armenian, Grant R Williams, Smita Bhatia
BACKGROUND: Autologous peripheral blood stem cell transplantation (aPBSCT) is the standard of care for adults with relapsed lymphoma, yet recipients remain at risk of developing chronic health conditions (CHCs). It was hypothesized that body composition measurements of skeletal muscle and fat are associated with late-onset CHCs and nonrelapse mortality after aPBSCT. METHODS: Leveraging the Blood or Marrow Transplant Survivor Study, we examined association between pre-aPBSCT body composition and new-onset grade 3-5 CHCs among 187 adults with lymphoma treated with aPBSCT (2011-2014) surviving ≥2 years after aPBSCT...
April 5, 2024: Cancer
https://read.qxmd.com/read/38577874/mismatched-related-donor-allogeneic-haematopoietic-cell-transplantation-compared-to-other-donor-types-for-ph-chronic-myeloid-leukaemia-a-retrospective-analysis-from-the-chronic-malignancies-working-party-of-the-ebmt
#37
JOURNAL ARTICLE
Francesco Onida, Luuk Gras, Junran Ge, Linda Koster, Rose-Marie Hamladji, Jenny Byrne, Daniele Avenoso, Mahmoud Aljurf, Marie Robin, Kazimierz Halaburda, Jakob Passweg, Urpu Salmenniemi, Henrik Sengeloev, Jane Apperley, Andrew Clark, Péter Reményi, Elena Morozova, Francesca Kinsella, Stig Lenhoff, Arnold Ganser, Ka Lung Wu, Antonio Perez-Martinez, Patrick J Hayden, Kavita Raj, Joanna Drozd-Sokolowska, Guillermo OrtÍ, Hugues de Lavallade, Ibrahim Yakoub-Agha, Donal P McLornan, Yves Chalandon
Allogeneic haematopoietic cell transplantation (allo-HCT) remains an option for tyrosine kinase inhibitor-resistant chronic myeloid leukaemia (CML) in first chronic phase (CP1) and high-risk patients with advanced disease phases. In this European Society for Blood and Marrow Transplantation (EBMT) registry-based study of 1686 CML patients undergoing first allo-HCT between 2012 and 2019, outcomes were evaluated according to donor type, particularly focusing on mismatched related donors (MMRDs). Median age at allo-HCT was 46 years (IQR 36-55)...
April 5, 2024: British Journal of Haematology
https://read.qxmd.com/read/38576294/acute-graft-versus-host-disease-in-beta-thalassemia-patients-following-allogeneic-haematopoietic-stem-cell-transplantation
#38
JOURNAL ARTICLE
Nabila Rafique, Asghar Ali, Tariq Ghaffor, Tariq Azam Khattak, Muhammad Bilal Asghar, Qammar-Un-Nisa Chaudhry
OBJECTIVE: To analyse the frequency, risk factors, and clinical symptoms of acute graft-versus-host disease (aGvHD) in patients with beta-thalassemia major after allogeneic haematopoietic stem cell transplantation (HSCT). STUDY DESIGN: Descriptive study. Place and Duration of the Study: Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan, from January 2017 to December 2021. METHODOLOGY: Data were obtained from patients diagnosed with bone and tissue malignancies (BTM) who had undergone haematopoietic stem cell transplantation (HSCT) and experienced aGVHD...
April 2024: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://read.qxmd.com/read/38576284/impact-of-mll-af9-gene-rearrangement-on-survival-of-acute-myeloid-leukaemia-patients-an-insight-into-pakistani-population
#39
JOURNAL ARTICLE
Muhammad Tariq, Sadaf Shahab, Javeria Rauf Saeed, Zeeshan Hussain, Uzma Zaidi, Tasneem Farzana, Sultan Ahmad
OBJECTIVE: To ascertain the frequency of the MLL::AF9 gene rearrangement and its association with survival in Pakistani patients suffering from acute myeloid leukaemia (AML). STUDY DESIGN: Analytical study. Place and Duration of the Study: Department of Haematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan, from 2015 to 2020. METHODOLOGY: Patients without a history of past AML chemotherapy, aged from 10 to 75 years, were included...
April 2024: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://read.qxmd.com/read/38575401/consensus-of-the-brazilian-association-of-hematology-hemotherapy-and-cellular-therapy-on-patient-blood-management
#40
JOURNAL ARTICLE
Roseny Dos Reis Rodrigues, Denise Menezes Brunetta, Lorena Costa, Bruno Deltreggia Benites, Mariana Munari Magnus, Susankerle de Oliveira Costa Alves, Gil Cunha De Santis, Silvia Renata Cornélio Parolin Rizzo, Guilherme Rabello, Dante Mario Langhi Junior
Understanding the physiological concepts of oxygen delivery is essential to discern the mechanisms that influence its increase, reduction or maintenance in the body. This text explores the different mechanisms that help maintain oxygen delivery even in the face of reduced hemoglobin levels. Adequate oxygen delivery ensures tissue and metabolic balance, which is crucial to avoid harmful consequences such as metabolic acidosis and cellular dysoxia. The complex interaction between variables such as cardiac output, hemoglobin and heart rate (HR) plays a fundamental role in maintaining oxygen delivery, allowing the body to temporarily adjust to situations of anemia or high metabolic demand...
March 19, 2024: Hematology, Transfusion and Cell Therapy
keyword
keyword
68470
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.